Key regions: France, Europe, United Kingdom, Brazil, India
Lithuania, like many other countries, is experiencing a growing demand for oncology drugs. This trend is driven by a number of factors that are unique to the Lithuanian market.
Customer preferences: Patients in Lithuania are increasingly seeking out oncology drugs that offer targeted therapies and fewer side effects. This is in line with global trends, as patients become more informed about their treatment options and demand more personalized care. As a result, pharmaceutical companies are investing heavily in research and development to create drugs that are more effective and have fewer side effects.
Trends in the market: One of the key trends in the Lithuanian oncology drugs market is the rise of biosimilars. These are drugs that are similar to existing biologic drugs, but are produced by different manufacturers. Biosimilars are becoming increasingly popular in Lithuania due to their lower cost, which makes them more accessible to patients. This trend is expected to continue as more biosimilars are developed and approved for use in Lithuania.Another trend in the Lithuanian oncology drugs market is the growing use of immunotherapy. This is a type of cancer treatment that uses the body's own immune system to fight cancer cells. Immunotherapy has been shown to be highly effective in certain types of cancer, and is becoming an increasingly popular treatment option in Lithuania.
Local special circumstances: One of the unique factors driving the demand for oncology drugs in Lithuania is the country's aging population. As the population ages, the incidence of cancer is expected to increase, which will drive demand for oncology drugs. Additionally, the Lithuanian government has made significant investments in healthcare in recent years, which has led to improvements in cancer screening and treatment. This has also contributed to the growing demand for oncology drugs in the country.
Underlying macroeconomic factors: The Lithuanian economy has been growing steadily in recent years, which has led to increased healthcare spending. This has allowed the government to invest more in cancer screening and treatment, which has contributed to the growing demand for oncology drugs. Additionally, the country's membership in the European Union has made it easier for pharmaceutical companies to do business in Lithuania, which has led to increased competition and lower prices for oncology drugs.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
